J&J’s Gorsky Stands By Remicade Longevity As Biosimilar Impact Hits Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
"We expect the biosimilar market to behave quite differently" than generics, CEO Alex Gorsky says even as international sales of Remicade fell 20% in the second quarter, though largely due to currency.